Each tumor specimen was screened for mutations in EGFR exons 18–21 and KRAS exon 2, and mutation status was then compared with sensitivity to the two drugs.

A dding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...